This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Medicenna Therapeutics, Inc
Drug Names(s): IL-4 PE, NBI-3001, PRX-321
Description: NBI-3001 is a recombinant fusion of the cytokine IL-4 and a Pseudomonas exotoxin. The protein binds to the IL-4 receptor and can kill cells expressing this receptor.
IL-4 receptors are enriched on certain brain tumor cells. NBI-3001 is administered using catheter directly to regions of the brain near the tumor.
In December 2002, Neurocrine announced plans to license NBI-3001 to a partner. In July 2006, Protox Therapeutics acquired the program from Neurocrine and the U.S. Public Health Service (PHS). Protox has committed to pay PHS and Neurocrine, for the license and corresponding assets, up to US$2 million through 2009. In addition, Protox will pay PHS up to US$4 million in future milestone payments (based on the compound receiving FDA approval for at least three indications), as well as royalties on commercial sales.
Medicenna acquired MDNA55 from Protox.
Partners: Neurocrine Biosciences, Inc.
Additional information available to subscribers only: